Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody

Clinical and Experimental Immunology

Volumn 133, Issue 3, 2003, Pages 485-492

  Meijer, R T ^a   Surachno, S ^a   Yong, S L ^a   Bemelman, F J ^a   Florquin, S ^a   Ten Berge, I J M ^a   Schellekens, P T A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Immunosuppression; Monoclonal antibody; Rejection therapy; Renal transplantation

Indexed keywords

CD3 ANTIGEN; CYCLOSPORIN A; CYTOKINE; IMMUNOGLOBULIN A; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY CD3; OKT 3; PREDNISOLONE; PROMETHAZINE; T LYMPHOCYTE RECEPTOR;

ADULT; ANURIA; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DYSPNEA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HEADACHE; HUMAN; HYPOTENSION; HYPOVOLEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; MYALGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE; VOMITING;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CYCLOSPORINE; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN A; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; PREDNISOLONE; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 0042326411     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02200.x     Document Type: Article

References (33)

1. Ferran C, Dautry F, Mérite S et al. Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. J Clin Invest 1994; 93:2189-96.
2. Raasveld MHM, Bemelman FJ, Schellekens PTA et al. Complement activation during OKT3 treatment: a possible explanation for respiratory side effects. Kidney Int 1993; 43:1140-9.
3. Chatenoud L, Ferran C, Reuter A et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-γ. N Engl J Med 1989; 320:1420-1.
4. Parlevliet KJ, Ten Berge IJM, Yong SL, Surachno J, Wilmink JM, Schellekens PTA. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants. J Clin Invest 1994; 93:2519-25.
5. 2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 1990; 49:1117-23.
6. Anasetti C, Martin PJ, Storb R et al. Treatment of acute graft-versus-host disease with a non-mitogenic anti-CD3 monoclonal antibody. Transplantation 1992; 54:844-51.
7. Norman DJ, Vincenti F, de Mattos AM et al. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation 2000; 70:1707-12.
8. Waid TH, Lucas BA, Thompson JS et al. Treatment of renal allograft rejection with T10B9.1A31 or OKT3. Final analysis of a phase II clinical trial. Transplantation 1997; 64:274-81.
9. 1 (Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999; 68:608-16.
10. Friend PJ, Hale G, Chatenoud L et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 1999; 68:1632-7.
11. Van Lier RAW, Boot JHA, De Groot ER, Aarden LA. Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems. Eur J Immunol 1987; 17:1599-604.
12. Colvin RB, Cohen AH, Saiontz C et al. Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation. J Am Soc Nephrol 1997; 8:1930-41.
13. Nickeleit V, Vamvakas EC, Pascual M, Poletti BJ, Colvin RB. The prognostic significance of specific arterial lesions in acute renal allograft rejection. J Am Soc Nephrol 1998; 9:1301-8.
14. Meijer RT, Koopmans RP, ten Berge IJM, Schellekens PTA. Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen. J Pharmacol Exp Ther 2002; 300:346-53.
15. Gaber LW, Moore LW, Alloway RR et al. Correlation between Banff classification, acute renal rejection scores and reversal of rejection. Kidney Int 1996; 49:481-7.
16. Parlevliet KJ, Bemelman FJ, Yong SL et al. Toxicity of OKT3 increases with dosage: a controlled study in renal transplant recipients. Transpl Int 1995; 8:141-6.
17. + lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo. Eur J Immunol 1992; 22:993-9.
18. - T cell subset contains specialized primed T cells. J Immunol 1995; 154:17-25.
19. + T cells. J Exp Med 1997; 186:1407-18.
20. Helle M, Boeye L, de Groot E, de Vos A, Aarden LA. Sensitive ELISA for interleukin-6; detection of IL-6 in biological fluids: synovial fluids and sera. J Immunol Meth 1991; 138:47-52.
21. Van der Poll T, Jansen J, Levi M, ten Cate H, ten Cate JW, van Deventer SJH. Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med 1994; 180:1985-8.
22. Ortho Multicenter Transplant Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313:337-42.
23. Hirsch RL, Layton PC, Barnes LA, Kremer AB, Goldstein G. Orthoclone OKT3 treatment of acute renal allograft rejection in patients receiving maintenance cyclosporine therapy. Transplant Proc 1987; 19:S32-6.
24. Fox A, Harrison LC. Innate immunity and graft rejection. Immunol Rev 2000; 173:141-7.
25. Buysmann S, Bemelman FJ, Schellekens PTA, van Kooyk Y, Figdor CG, ten Berge IJM. Activation and increased expression of adhesion molecules on peripheral blood lymphocytes is a mechanism for the immediate lymphocytopenia after administration of OKT3. Blood 1996; 87:404-11.
26. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272:60-6.
27. Meijer RT, Yong SL, ten Berge IJM, van Lier RAW, Schellekens PTA. Non FcR-binding murine anti-human CD3 monoclonal antibody is capable of productive TCR signalling and induces proliferation in the presence of costimulation. Clin Exp Immunol 2001; 123:511-9.
28. 1 (Ala-Ala). J Clin Invest 2003; 111:409-18.
29. Roosnek EE, Van Lier RA, Aarden LA. Two monoclonal anti-CD3 antibodies can induce different events in human T lymphocyte activation. Eur J Immunol 1987; 17:1507-10.
30. Buysmann S, Hack CE, van Diepen FNJ, Surachno J, ten Berge IJM. Administration of OKT3 as a two-hour infusion attenuates first-dose side effects. Transplantation 1997; 64:1620-3.
31. Parren PWHI, Geerts MEJ, Boeije LCM, Aarden LA. Induction of T cell proliferation by recombinant mouse and chimeric mouse/human anti-CD3 monoclonal antibodies. Res Immunol 1991; 142:749-63.
32. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt auto-immunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994; 91:123-7.
33. Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset type I diabetes mellitus. N Engl J Med 2002; 346:1692-8.